Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 98 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cirrhosis Alcoholic Clear all
Suspended Phase 3 Interventional Results available

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

NCT04104321
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Aramchol free acid, Placebo
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Miami, Florida • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 6, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.

NCT04579874
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation, Liver Steatoses
Interventions
LIVERFASt
Diagnostic Test
Lead sponsor
Fibronostics USA, Inc
Other
Eligibility
18 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Detroit, Michigan • St Louis, Missouri • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 6, 2026, 9:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound

NCT01208311
View directory record Official record
Conditions
Alcoholism, Cirrhosis, Hepatitis c
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2016
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 6, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05364931
View directory record Official record
Conditions
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions
Cotadutide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
29
States / cities
Tucson, Arizona • Canoga Park, California • Gilroy, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 6, 2026, 9:27 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 6, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

NCT03987451
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
Chandler, Arizona • Peoria, Arizona • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 6, 2026, 9:27 AM EDT
Active, not recruiting Not applicable Interventional

A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)

NCT04820036
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Function, Obesity, Liver Fibroses
Interventions
Insulin Resistance, Quality of Life Assessment, Liver Function Test, Radiologic features of NASH, Serologic features of NASH
Diagnostic Test · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 6, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05809934
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 6, 2026, 9:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Collection Biorepository for Liver Disease Research

NCT03025074
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 6, 2026, 9:27 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

NCT04365868
View directory record Official record
Conditions
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
Interventions
belapectin, Placebo
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
81
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 6, 2026, 9:27 AM EDT
Terminated No phase listed Observational

Utilization of MAsS in Patients Undergoing LT for HCC

NCT05184283
View directory record Official record
Conditions
NAFLD, Hepatocellular Carcinoma, Liver Diseases, Liver Cancer, Cirrhosis, Liver, Hepatitis C
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 6, 2026, 9:27 AM EDT
Not listed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

NCT05402371
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
Interventions
Rencofilstat, Placebo
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
39
States / cities
Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 6, 2026, 9:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
MGL-3196, Placebo, Liver Biopsy
Drug · Procedure
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
90
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 6, 2026, 9:27 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082
View directory record Official record
Conditions
Hepatobiliary Diseases
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 6, 2026, 9:27 AM EDT
Not listed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

NCT03205345
View directory record Official record
Conditions
Decompensated Cirrhosis
Interventions
Emricasan (25 mg), Emricasan (5 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
76
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 6, 2026, 9:27 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

NCT05604287
View directory record Official record
Conditions
Healthy Participants
Interventions
ID119031166M, Placebo
Drug
Lead sponsor
IlDong Pharmaceutical Co Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 6, 2026, 9:27 AM EDT
Active, not recruiting No phase listed Observational

LITMUS Imaging Study

NCT05479721
View directory record Official record
Conditions
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years to 100 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 6, 2026, 9:27 AM EDT
Terminated No phase listed Observational

Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

NCT00375011
View directory record Official record
Conditions
Cirrhosis
Interventions
Not listed
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 6, 2026, 9:27 AM EDT
Completed Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

NCT04197479
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Placebo, Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
76
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 6, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Weight Management in Nonalcoholic Steatohepatitis

NCT00266019
View directory record Official record
Conditions
Fatty Liver
Interventions
Weight Management (diet, exercise, and behavior modification)
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 6, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

NCT05022693
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
BIO89-100
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 6, 2026, 9:27 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

NCT02193867
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 8 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 6, 2026, 9:27 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

NCT01672866
View directory record Official record
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 6, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Pegfilgrastim in Patients With Alcoholic Hepatitis

NCT02776059
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Standard of care + pegfiltrastim, Standard of care
Drug
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Loma Linda, California • Long Beach, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 6, 2026, 9:27 AM EDT